Neuropsychiatric aspects of paediatric brain tumours: An update by Khairkar, Praveen et al.
Romanian Neurosurgery  |  Volume XXX  |  Number 4 |  2016  |  October - December 
 
Article 
 
Neuropsychiatric aspects of paediatric brain 
tumours: an update  
 
Praveen Khairkar, Srikanth Reddy, Amit Agrawal 
INDIA 
 
 
 
DOI: 10.1515/romneu-2016-0077 
 
  
 
 
 
Romanian Neurosurgery (2016) XXX 4: 479 – 492 | 479 
 
 
 
 
 
 
 
DOI: 10.1515/romneu-2016-0077   
Neuropsychiatric aspects of paediatric brain tumours: an 
update 
Praveen Khairkar, *Srikanth Reddy, Amit Agrawal** 
Associate Professor, Department of Psychiatry, *Senior Resident, Department of Psychiatry, 
Mahatma Gandhi Institute of Medical Sciences, Sevagram, Wardha, Maharashtra, INDIA 
**Professor, Department of Neurosurgery, Narayna Medical College Hospital, Nellore, INDIA 
 
Abstract: The diagnosis and treatment of children and adolescents with cancer has a 
tremendous and lasting effect on the patients, their families, and other individuals in 
their social network. It carries a host of psychological and neurobehavioral ramifications, 
from questions of mortality to changes in levels of functioning in multiple domains. 
Childhood cancer remains the leading cause of illness-related death in childhood, but 
significant advances in survival have been made in the past 40 years. This review looks 
at the neuropsychiatric presentations, psychosocial and treatment-related issues that 
arise in children with brain tumors. 
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Background 
Psycho-oncology addresses the two major 
psychiatric and psychological dimensions of 
pediatric cancer; first, the psychiatric 
comorbid disorders and psychological 
responses of children at all stages of illness and 
their families and, the psychological stresses 
on health professionals delivering their care; 
and second the psychological, behavioural, 
and social factors that influence cancer risk, 
detection, and survival. (1) Though pediatric 
cancers constitute a very small portion of the 
total cancers diagnosed, accounting to only 2% 
of the total cancers, they remain one of the 
leading causes of illness related death in 
childhood. (2) Brain tumors constitute the 
second most common tumors in the pediatric 
age group after the leukemias. (3) Pediatric 
brain tumors are not similar to adult tumors. 
Meningioma, malignant gliomas, 
schwannomas and pituitary tumors are 
common in adults; however these tumors are 
rare in children. (4-5) In children more than 
50% of the brain tumours are infratentorial 
and the common tumours are low grade 
gliomas and primitive neuroectodermal 
tumours. (6-7) Gliomas represent 45 – 50% of 
all the pediatric primary brain tumors and are 
by far the commonest of them. (8) To 
appreciate the experience of a child who has 
cancer it is helpful to have an understanding of 
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the treatments involved. Treatment of 
pediatric cancer may involve chemotherapy, 
radiation, surgery, or stem cell/bone marrow 
transplant, or some combination of these 
modalities. In contrast, children with primary 
CNS malignancies, the second most common 
cancer of childhood, may have surgery only 
(eg, children with a pilocytic astrocytoma) or 
have surgery, radiation, and intensive 
chemotherapy (eg, children with 
medulloblastoma). (9) 
Significant advances in treatment of 
pediatric brain tumors had influenced the 
survival rate in the past 40 years. The overall 5-
year survival rate for 0- to 16-year-olds 
diagnosed between 1975 and 1979 was 62.9%, 
compared with 81.5% in 2005.9-10  Much of 
this progress has come from the collaboration 
of pediatric oncology researchers and 
clinicians. The Children’s Oncology Group 
(COG), supported by the National Cancer 
Institute, creates standardized treatment 
protocols for pediatric cancers and then 
analyzes the responses to care and 
disseminates this information to all pediatric 
cancer providers. (11) The degree of emotional 
expressiveness in children with brain tumor 
(s) and its possible effect on prognosis have 
been the subject of interest of a large body of 
literature. Few descriptive case reports noted 
shorter survival both in adolescent and adult 
patients with depressed, resigning attitude 
compared with patients who were able to 
express more negative emotions, such as 
anger. (12) Other clinical and epidemiological 
studies have not supported such an influenced 
in cancer risk or in cancer mortality. (13)  This 
review looks at the neuropsychiatric 
presentations, psychosocial and treatment-
related issues that arise in children with brain. 
Neuropsychiatric Presentations: 
Brain tumours can be either supratentorial 
or infratentorial depending upon whether they 
arise from above or below the tentorium. The 
subjects having tumours in the supratentorial 
space manifest convulsions more frequently, 
whereas subjects having tumours in the 
infratentorial space manifest problems related 
to balance, posture and cranial nerve 
functions. Interestingly, morning headaches, 
nausea, and lethargy resulting from tumour 
obstruction of the ventricles and raised 
intracranial tension are some of the common 
presentations of both of them. (14) 
Neuropsychiatric presentations in children 
with brain tumour commonly changes over 
the course of illness and depends on medical, 
psychological and social factors: the disease 
itself (i.e., site, symptoms, clinical course, side 
effects of chemotherapeutic agents or 
radiations); prior levels of adjustment; the 
threat that cancer poses to attaining age 
appropriate developmental tasks and goals; 
cultural, religious and spiritual attitude; 
presence of emotionally supportive persons or 
caregivers; the potential for psychological and 
physical rehabilitation; and finally child’s 
temperament and coping style as well as prior 
experience with loss. (15) Unlike in adults with 
brain tumours in whom the wide spectrum of 
neuropsychiatric presentations are being 
reported the focus in pediatric age group has 
been largely on issues of adjustment, 
emotional and mood disorder and cognitive 
impairment. Let us discuss issues related to 
adjustments.  
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Adjustment problems: 
Similar to any other significant stressor, 
child has problems in adjusting himself to the 
truth of having a critical illness such as brain 
tumour. Pediatric patients who survive brain 
tumors cope with the direct physiological 
insult caused by the tumor itself, the 
treatments (neurosurgery, chemotherapy, 
and/or high dose central nervous system 
irradiation) and treatment related squeal (e.g., 
impaired health, extensive school absence, 
familial stress). Coping of these psychological 
problems may be different for children of 
different age group. In preschool age, the child 
is mostly occupied with magical thinking and 
believes that he suffering from any chronic 
illness is a punishment given to him for some 
trivial wrong deeds. As the preschool children 
spend most of the time with their family, 
separation from them for the purpose of the 
treatment can be very traumatic to the child. 
In school, the child may face disrupted 
functioning and problems with peer 
relationship. This social squeal can be handled 
by involving child in activities such as board 
games, computers etc., and educational help 
can be provided by offering school tutors. It’s 
not until adolescence, that the child is able to 
understand the complexity of the chronic 
illness. (16) The common distresses that the 
teenager experiences after being diagnosed of 
cancer are “loosing hair”, “missing leisure 
activities”, “fatigue”, “pain from procedures 
and treatment” and “worry about missing 
school”. (17) In adolescence, the patients are 
not able to form intimate relationships as a 
result of negative self-image and pessimistic 
attitudes.  This adds to their loneliness and 
restricted availability of coping resources. 
Both of these are challenged during treatment 
because of feelings of being different and 
physical appearance changes such as hair loss 
caused by chemotherapy or weight gain caused 
by corticosteroids. As a result of low self-
esteem and body image concerns expressed by 
adolescents with cancer, they avoid or are less 
likely to establish intimate relationships.18 
Future concerns about fertility, threatened by 
cancer treatment, is also a prominent issue. 
Semen cryopreservation is available for boys 
but there are no definitive preservation 
methods available for girls. (19) These 
psychological adjustment problems make the 
children with brain tumors susceptible to 
various psychiatric illnesses such and mood 
disorder and anxiety disorder.  
Emotional/ Anxiety/Mood disorders 
One might assume that a severe stressor 
such as a diagnosis of cancer during childhood 
would overwhelm an individual’s ability to 
cope emotionally and most if not all children 
would experience emotional difficulties. 
However, studies suggest that most children 
with cancer do not exhibit significant levels of 
depression or anxiety, although a significant 
minority do experience marked levels of 
psychological distress. (20–23) Some clinical 
observations have indicated that a subset of 
patients exhibit more problems, such as 
greater difficulty coping. (22) Other studies 
show the emotional well-being of children 
with cancer currently receiving chemotherapy 
to be remarkably similar to case-control 
classroom peers, (23) and initial studies of 
cancer survivors similarly failed to find 
increases in social and emotional problems in 
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children with cancer, (24) although new data 
on survivors has challenged this view.  
In assessing a child’s mood, the clinician 
must be knowledgeable about the side effects 
of the treatments, which may include fatigue, 
decreased appetite, and disturbed sleep. If a 
child does present with clinically significant 
depressive symptoms, the treatment follows 
the same course as it would in the physically 
well child; that is, with psychotherapy such as 
cognitive-behavioral therapy (CBT) and 
antidepressant medication as indicated. (25) 
Although no large studies have been 
conducted in children with cancer, selective 
serotonin reuptake inhibitor (SSRI) 
medications are the pharmacologic 
antidepressant treatment of choice, as they are 
in the population at large. (26) In an 
uncontrolled pilot study of 15 children with 
cancer and depression or anxiety, fluvoxamine 
was well tolerated and effective. (27) In 
another small study, 7% of children involved 
in National Institutes of Health (NIH) 
research trials for cancer were found to have 
been prescribed antidepressant medication. 
(28) The investigators of this study noted 
increasing acceptance for 
psychopharmacologic treatment of 
subthreshold psychiatric disorders to improve 
quality of life, and concluded that in addition 
to psychological support always being 
indicated in the setting of anxiety or 
depression, there is a role for the judicious use 
of psychotropic medications. 
The child with cancer often presents to 
mental health treatment with anticipatory 
anxiety and/or nausea and vomiting. There are 
no documented incidence or prevalence 
studies on particular or specific type (s) of 
anxiety spectrum disorders developed after 
brain tumors. However, anticipatory anxiety 
without nausea or vomiting component is 
initially addressed with behavioral 
interventions. The child may feel nauseated or 
vomit on arriving at the outpatient clinic or 
hospital. One study reports 59% of children 
experienced mild to severe anticipatory nausea 
and vomiting despite the use of ondansetron. 
(29) In mild cases, the effective behavioral 
approaches include thought stopping, 
hypnosis, distraction, and relaxation. (30) 
More severe cases of such typified 
presentations in association with post-
chemotherapy nausea and vomiting may 
respond to increased use of antiemetics, 
including higher doses of ondansetron, 
corticosteroids, and benzodiazepines. There 
are also some data to support the use of 
acupuncture in this population. (31) 
Treatment related issues:  
In the psychiatric evaluation and treatment 
of children with cancer, several prominent 
areas of difficulty related to cancer treatment 
emerge, and include psychiatric effects of 
chemotherapeutic agents, neurocognitive 
effects of treatment from chemotherapy and 
cranial radiation, and issues related to 
adherence with treatment. For the sake of 
understanding, the neuropsychiatric adverse 
effects of most commonly prescribed and 
reported drugs viz. corticosteroids and 
interferon are discussed below.   
Corticosteroids 
Corticosteroids are routinely used for the 
treatment of childhood cancers and their 
sequelae. In many chemotherapy protocols, 
including leukemias and lymphomas, 
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corticosteroids play a central role. The 
appearance of adverse psychiatric symptoms is 
common in children who are receiving high-
dose corticosteroids. These symptoms include 
changes in mood, sleep, and appetite. Research 
in the area of psychiatric adverse effects to 
corticosteroids is much more extensive in 
adults than in children. The adult literature 
supports the role of corticosteroids in causing 
behavioral changes including depression, 
mood elevation, irritability, anger, insomnia, 
and excess talkativeness. (32–34) Psychiatric 
sequelae are usually dose-dependent and 
studies have reported increased severity of 
psychiatric symptoms with higher doses of 
corticosteroids. Patients can become severely 
depressed, manic, psychotic and/or delirious. 
In the largest study of its type, severe 
psychiatric reactions were seen in 1.3% of 
patients receiving prednisone 40 mg per day or 
less; in 4% to 6% of patients receiving 41 to 80 
mg per day; and in 18.4% of patient receiving 
more than 80 mg per day. (35) The use of 
corticosteroids in children has been studied in 
children with renal, pulmonary, and 
gastrointestinal diseases more commonly than 
in children with cancer and reviewed 
extremely well by Satel. (36) Effects seen in 
children with cancer are consistent with the 
behavioral changes seen in children with other 
illnesses and in the adult population. In 
children receiving prednisone at a dosage of 60 
mg/m2/d for leukemia and lymphoma, 
increased irritability, argumentativeness, 
tearfulness, reports of “talking too much,” 
tiredness, low energy, and night waking were 
common symptoms, with a trend toward more 
symptoms in younger children. (37) In 
children with ALL, groups receiving 
prednisone 40 mg/m2/d and 120 mg/m2/d 
showed adverse changes in 
attention/hyperactivity, emotionality, sleep 
disturbance, depressed mood, listlessness, and 
peer relations, although there was no 
significant difference between the two steroid 
groups. (38) In a few cases, the severity of a 
child’s depression or mania or the 
development of psychosis requires a reduction 
or discontinuation of the corticosteroids as 
well as acute psychopharmacologic 
intervention. For mild forms of depression, 
psychotherapeutic strategies can be beneficial. 
Psychoeducation for patients and families that 
symptoms may be transient and biochemically 
mediated rather than the result of a sudden 
giving up or self-pity is essential. (39)  
Neurocognitive deficits 
Apart from adjustment problems and 
emotional disorders in children, neuro-
cognitive deficits are of a great concern and 
interest in subjects of brain tumours and their 
incidence is found to be unacceptably high. 
The incidence is variable with some reports 
stating it to be present in more than 50% of 
paediatric cancers (2), whereas some reports 
put it at 40% – 100% among long term brain 
survivors (40) and some go on to state that 
impaired intelligence is present in 90% of 
conventionally treated medulloblastoma 
patients. (41)  Despite the differences between 
ALL and malignant brain tumors, there are 
significant similarities among the symptoms 
comprising neurocognitive deficits, 
particularly with regard to the treatments of 
brain irradiation and intrathecal 
chemotherapy. While a considerable body of 
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evidence has accumulated on the nature of 
white matter damage from those treatments, 
variations in tumor pathology and combined 
treatment protocols over time have made the 
need for further research necessary. In order to 
summarize our understanding of the 
neuropsychological impact of childhood 
cancers and their treatment, we have chosen to 
define core deficits, which involve executive 
functions, processing, and fluid abilities, and 
secondary deficits, which are knowledge based 
and oftentimes referred to as crystallized 
abilities. In the current conceptualization, it is 
the detrimental effects of cancer and cancer 
therapy on the biological substrates of core 
abilities that eventually result in more 
observable secondary deficits. Several 
excellent reviews are available supporting this 
approach to understanding neurocognitive 
deficits among children surviving brain 
tumors (42), suggesting that children 
surviving brain tumors are at greater risk for 
more severe deficits because of the increased 
aggressiveness of their therapy and, in 
particular, the continued use of CRT. While 
the late effects of CRT typically emerge within 
1 to 2 years of administration, there is evidence 
that brain-damage effects may be delayed up 
to 7 years. (43) Children who survive a brain 
tumor do appear to be at risk for social 
difficulties following cessation of treatment, 
perhaps due to increased severity of 
neurocognitive injury. (44) These core and 
secondary symptoms of neurocognitive 
deficits may also impact other areas of 
functioning, such as social interactions. The 
major core neurocognitive deficits and risk 
factors among children treated for malignant 
brain tumors. 
Premorbid factors 
The occurrence of neurocognitive deficits 
depend on various premorbid factors such as 
female sex, younger age at treatment, genetic 
polymorphisms, and population and social 
risk factors. (45) As compared to older 
counterparts, a younger age at treatment 
consistently shows a significantly greater 
decline in age-adjusted scaled scores of 
intellectual functioning over time. In couple of 
the studies by same author, the subjects of 
medulloblastoma who were younger (<8.85 
years) experienced more neurotoxicity, when 
measured on tests of intellectual functioning, 
than those who were older at treatment (>8.85 
years). (46-470 Similar findings were reported 
demonstrating significantly greater declines in 
age-adjusted scaled scores of factual 
knowledge and nonverbal abstract thinking as 
well as an overall estimate of full-scale IQ in 
younger subjects receiving radiation treatment 
for medulloblastoma. (48) Like younger age, 
female gender also correlated with poorer 
neurocognitive functions as compared to 
males having solid brain tumors when 
measuring for intellectual and academic 
functioning, including a test of reading 
comprehension. (49) Moreover in comparison 
to males, early age of diagnosis and low social 
economic status were associated with more 
severe cognitive impairment in females. (50) 
Other pre-morbid factors predicting the 
neurocognitive deficits in paediatric subjects 
of brain tumours are genetic polymorphisms, 
and population and social risk factors. (51-52) 
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Sources of neurocognitive deficits 
Neurocognitive deficits can occur by 
myriad of causes ranging from primary CNS 
tumour effects, neurosurgical squeal, raised 
intracranial tensions, seizures and 
antiepileptic treatments, cranio-spinal 
radiotherapies and systemic and CNS focused 
chemotherapies. (53) The growing tumour as 
well as the raised intracranial pressure 
occurring mostly as a result of obstructive 
hydrocephalus causes compression of tissue at 
both local and remote sites. Hydrocephalus is 
involved with problems of neurocognitive 
functioning including memory, attention and 
perceptual performance. (54) One study 
demonstrated an association between 
presence of hydrocephalus and a higher risk 
for intellectual deficits in paediatric brain 
tumour subjects. (55) However early 
correction of hydrocephalus may result in no 
lasting effect on cognitive functioning. (56) 
Similarly extent of resection in neurosurgery 
has also been associated with deficits in 
intellectual functioning with higher decline 
associated with more extensive resection. (57) 
Posterior fossa syndrome (mutism, ataxia and 
behavioural changes), developing after surgery 
has a higher risk for neuropsychiatric squeal. 
(58, 59) Further studies demonstrated that the 
surgical resection of brain tumours without 
adjuvant therapy was itself associated with 
deficits in neuropsychological testing in 
attention, memory, processing speed, and 
visuospatial processing, and a variety of 
behavioral problems. Moreover other factors 
such as shunt infections, meningitis or the 
need for repeat surgery further increased the 
risk of cognitive decline. (60, 61) Exposure to 
cranial radiotherapy while getting treated for 
brain tumours has also shown to be 
responsible for the cognitive decline. It is 
postulated to cause greatest damage to 
developing white matter and as a result has 
been shown to cause the greatest negative 
squeal for the developing brain. Myelination 
normally continues after birth into the third 
decade of life (62) and exposure to CRT can 
disrupt this developmental process, ending in 
demyelination, and ultimately white matter 
damage. In addition, immature 
oligodendrocytes are thought to be more 
vulnerable to injury than the mature 
counterparts. (63) Treatment with cranial 
radiotherapy has shown to reduce the IQ by 15 
to 25 points in children with brain tumors. (64, 
65) In view of these findings of significant 
cognitive decline, efforts are now shifted to 
develop new protocols having the advantage of 
decreasing the radiation exposure while 
maintaining the same cure rate. These efforts 
involve using early focal radiotherapy and 
decreasing the target tissue volume and dose of 
cranial radiation. (66) Like radiotherapy, 
chemotherapy with agents such as 
methotrexate has also shown to cause 
neurocognitive deficits though not as severe as 
the former. Methotrexate is known to interfere 
with folate metabolism resulting in 
demyelination and other toxic effects on CNS 
thereby leading to cognitive decline. (67) 
Problems that are reported with the use of 
chemotherapy in treatment of pediatric brain 
tumors are problems with sustained attention, 
which correlated with teacher reports of 
poorer academic performance, particularly in 
mathematics, increased internalizing 
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behaviors on the Child Behavior Checklist, a 
parent report measure of social competence 
and behavior problems, visual processing, 
visual-motor functioning, attention and 
executive functioning, academic performance, 
verbal abilities, and memory with female 
gender and young age (particularly less than 
age 3 years) as risk factors. (68-70)   
Psychopharmacological and palliative care 
interventions for neurocognitive effects: 
Although the research on the pattern and 
causes of neurocognitive deficits in pediatric 
brain tumors has been rapidly progressing 
over the last few decades, the development of 
empirically validated treatment for these 
deficits is still in its infancy. The role of 
psychiatrists and psychologists in identifying, 
assessing and dealing with these deficits 
cannot be underestimated. As in any child 
with academic difficulties and cognitive 
impairments, mental health professionals 
should strive towards educating family 
members and school personnel about the 
deficits that are expected to develop as the 
treatment progresses and also advocating for 
proper services. The management can be a 
primary prevention wherein, the CNS insult is 
tried to be reduced in order to prevent 
development of neurocognitive deficits. As 
radiotherapy is known to cause the maximum 
CNS insult, protocols are using lower doses of 
cranial radiation, decreasing the tissue target 
volume, and postponing radiation in the 
highest risk groups or using early focal 
radiotherapy to minimize the cognitive effects. 
(71) Newer forms and techniques for 
delivering radiation are also being used. For 
example, proton beam radiotherapy, as 
opposed to standard photon radiotherapy, 
may decrease the likelihood of significant 
neurocognitive decline, because there is no 
exit radiation dose thereby decreasing the 
volume of white matter involved. In addition 
to morbidity-limiting strategies to minimize 
the neurotoxic effects (particularly cranial 
radiation), some investigators have examined 
interventions for neurocognitive effects after 
they have occurred. (72, 73) As in any child 
with academic difficulties and cognitive 
impairments, mental health professionals 
working with survivors of cancer have a role in 
educating family members and schools about 
deficits seen in this population, and 
advocating for appropriate accommodations 
and services. Studies show that the decline in 
IQ may not be apparent initially and can be 
progressive over time, highlighting the 
importance of following children 
longitudinally.  One potentially useful 
addition to the development of interventions 
for cognitive deficits has been an appraisal of 
the influence of the family environment and 
resources following recovery from traumatic 
brain injury. The importance of family 
cohesiveness and stability in recovery from 
brain injury has long been known. As early as 
1958, it was reported that children who 
suffered a traumatic brain injury and 
developed psychiatric disturbance had greater 
degrees of family pathology as those who did 
not experience a mental disorder. (74) Other 
researchers have further demonstrated the 
relationship between family pathology and 
behavioral difficulties among brain injured 
children. (75, 76) More recently, Yeates and 
colleagues (77) (1997) have documented that 
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chaotic and dysfunctional family 
environments have a significant adverse 
impact on neurological and 
neuropsychological recovery from traumatic 
brain injury among school-age children. This 
relationship appears to be valid even when 
severity of brain injury and other medical 
factors were experimentally controlled (Max et 
al., 1999). (78) It appears that family burden, 
characterized by ratings from parents as to the 
negative impact of the child’s injury on the 
family, and overall family adjustment are 
significant predictors of continued 
neurobehavioral symptoms following 
childhood traumatic brain injury (Yeates et al., 
2001). (79)   How might these findings be 
relevant to survivors of childhood cancer 
having neurocognitive problems? One could 
speculate that the family environment might 
be of equal or greater importance in the 
treatment and recovery of a chronic life-
threatening disease compared with an acute 
event such as a traumatic brain injury. 
Certainly, educating parents to be advocates 
for their children by giving them sufficient 
information and support should be a 
component of any clinical intervention. 
Whether formal training in special skills 
would facilitate recovery of function among 
children treated for traumatic brain injury or 
cancer is not yet known. 
Adherence  
Adherence a more proactive term than 
compliance to treatment regimens is a 
prominent issue with children and adolescents 
having brain tumors. Adolescents consistently 
show higher rates of non-adherence compared 
with children and adults in the treatment of 
cancer and other life-threatening illnesses. 
(80-84) Risk factors for poor adherence with 
cancer treatment in adolescents have been 
identified, including low socioeconomic status 
of the family, (84–86) barriers to 
communication such as cultural and linguistic 
differences, (87) and mental illness, including 
depression in a parent and behavioral 
disturbances during the patient’s childhood.88 
Clinically, poor communication between 
adolescents and their parents around 
treatment seems to be a significant contributor 
to poor adherence. It is important to identify 
non-adherence issues early in treatment. 
Blood levels of a drug or its metabolites have 
been used to monitor adherence with oral 
medication regimens, such as 6-
mercaptopurine in the treatment of ALL. 
(85,86) A nonjudgmental inquiry about the 
patient’s consistency in taking the medication 
may be just as effective. (84)  Confusion about 
appropriate doses or about who is responsible 
for administering the medication may 
contribute to unintentional non-adherence. 
Psychological issues at the end of the life 
Although most children with cancer 
survive, childhood cancer remains the leading 
cause of illness-related death in childhood and 
is the second leading cause of death in 
children, behind accidents.  The reality of 
cancer as a sometimes terminal illness affects 
patients, families, and caregivers alike. 
Oncology teams utilize the services of social 
workers, psychologists, psychiatrists, 
chaplains, and child life specialists to assist the 
child, family, and staff with the challenges 
faced at the end of life. These care providers 
can facilitate family conversations about death 
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between parents and with the child. (89) 
Conversations about dying and end-of-life 
care are inherently difficult and often avoided, 
but data support having open conversations 
with children. Kreicbergs and colleagues (90) 
found that parents of children with severe 
malignant disease who had conversations with 
their children about dying did not regret these 
conversations. 
Children with cancer experience 
significant physical and psychological 
symptoms and suffering at the end of life. (91) 
Despite this, palliative care services are 
available at only 58% of institutions caring for 
pediatric oncology patients, highlighting one 
obstacle to offering optimal care to all children 
treated for cancer. (92) Many of the difficulties 
encountered in the terminal phase of children 
with cancer are common to all children at the 
end of life. See the article by Knapp and 
colleagues elsewhere in this issue for further 
exploration of this topic. 
Conclusions 
Neuropsychiatric presentations of 
pediatric brain tumors are both interesting 
and valuable in the midst of current concerns; 
interesting because it increases our 
understanding about presenting patterns and 
their mechanism of evolvement and useful 
because of the possibility of learning more and 
better from previous experiences of clinicians. 
Recent decades have brought about 
tremendous improvements in survival 
outcomes for children with cancer. Overall, 
children with cancer are resilient, but they are 
confronted with several challenges adjusting 
to their illness, dealing with treatment related 
effects, and for some facing end-of-life care. 
Children having brain tumours undergo 
various psychosocial stressors and related 
psychiatric problems such as mood disorders 
and neurocognitive deficits which need to be 
evaluated and assessed longitudinally in every 
child. These facts make the need that both 
mental health clinicians and pediatricians 
should play a critical role in providing the 
assessment, support, and treatment needed in 
the childhood cancer population. Continued 
research in this field is imperative. 
Incorporation of systematized psychiatric care 
in the routine management of paediatric brain 
tumours can improve the quality of life of the 
patients and make the oncology treatment 
complete. Continued research in this field is 
however imperative. 
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